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We reviewed the current status of thyroid fine-needle aspiration cytology (FNAC) in Korea. Thy-
roid aspiration biopsy was first introduced in Korea in 1977. Currently, radiologists aspirate the 
thyroid nodule under the guidance of ultrasonography, and cytologic interpretation is only legally 
approved when a cytopathologist makes the diagnosis. In 2008, eight thyroid-related societies 
came together to form the Korean Thyroid Association. The Korean Society for Cytopathology 
and the endocrine pathology study group of the Korean Society for Pathologists have been 
updating the cytologic diagnostic guidelines. The Bethesda System for Reporting Thyroid Cyto-
pathology was first introduced in 2009, and has been used by up to 94% of institutions by 2016. 
The average diagnosis rates are as follows for each category: I (12.4%), II (57.9%), III (10.4%), 
IV (2.9%), V (3.7%), and VI (12.7%). The malignancy rates in surgical cases are as follows for 
each category: I (28.7%), II (27.8%), III (50.6%), IV (52.3%), V (90.7%), and VI (100.0%). Liquid-
based cytology has been used since 2010, and it was utilized by 68% of institutions in 2016. The 
categorization of thyroid lesions into “atypia of undetermined significance” or “follicular lesion of 
undetermined significance” is necessary to draw consensus in our society. Immunocytochemistry 
for galectin-3 and BRAF is used. Additionally, a molecular test for BRAF in thyroid FNACs is actively 
used. Core biopsies were performed in only 44% of institutions. Even the institutions that perform 
core biopsies only perform them for less than 3% of all FNACs. However, only 5% of institutions 
performed core biopsies up to three times more than FNAC.
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▒ REVIEW ▒
In this review, we surveyed the current status of thyroid fine- 
needle aspiration cytology (FNAC) in Korea and briefly described 
the history of FNAC in Korea. The multiple topics covered in 
this review include thyroid cytology sample collectors and inter-
preters, cytotechnician training programs, preparation methods 
for thyroid cytology samples, staining of thyroid cytology samples, 
thyroid cytology reporting systems and data distribution, the 
use of “atypia of undetermined significance” and “follicular lesion 
of undetermined significance” (AUS/FLUS) as diagnostic categories, 
the thyroid cytology audit program, correlation between cytology 
and histology, external quality assurance for thyroid FNAC, and 
the status of ancillary testing including core biopsy.
The 2016 survey project was designed to create a short commu-
nication that was compiled by a limited number of members of 
the Korean Society for Cytopathology (KSC). The 2012 survey1 
is more comprehensive than this 2016 survey, but we compared 
2012 and 2016 data in this paper. We asked the KSC to admin-
ister the survey to the 210 institutions under its quality control. 
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Thirty-eight institutions responded to this survey within 3 weeks. 
The survey items included thyroid cytology sample collectors 
and interpreters, preparation methods for thyroid cytology 
samples, thyroid cytology reporting systems and data distribu-
tion, the use of AUS/FLUS categorization, correlation between 
cytology and histology, and the status of core biopsy. Twelve 
among the 38 responders answered distribution data for each 
class of the Bethesda reporting system. Eight institutions also 
sent correlation data between cytology and histology. Graphs 
and statistical analysis of Student’s t test for categorical diagnosis 
rates were constructed using Excel Software. Categorical vari-
ables were expressed as percentage, frequency, and range. Dif-
ferences were considered statistically significant at p < .05.
BRIEF HISTORY OF THYROID FINE-NEEDLE 
ASPIRATION CYTOLOGY 
In Europe, thyroid FNAC was introduced in the 1950s,2 but 
in the United States, it began to be more actively used in the 
1970s.3 Thyroid aspiration biopsy was first introduced in Korea 
by a physician in 1977.4 As for the introduction of FNAC to 
pathologists, it was started by a pathologist who was experi-
enced in aspiration cytology from cytopathology training in 
Europe in the 1980s.5 In the early stages of use, aspirations were 
initially performed by a radiologist who had undergone Euro-
pean training, and the aspirates were sent to pathologists for in-
terpretation. At that time, clinicians directly interpreted the 
aspiration cytology slide; however, with the development of 
quality control and insurance coverage, the frequency of clini-
cian’s interpretation has decreased. Initially, aspiration cytology 
was performed only on palpable lesions of superficial organs, 
but with the development of imaging system, it has become 
possible to accurately locate and aspirate nonpalpable lesions 
with very high diagnostic accuracy. Therefore, FNAC has become 
prevalent at the majority of medical institutions.6 In 2006, pa-
thologists created management guidelines for patients with thy-
roid nodules and thyroid cancer as a mainstay of the Korean 
Endocrine Society.7 As a result, the Endocrine Pathology Study 
Group was created in 2007. In 2008, eight thyroid-related soci-
eties made up the Korean Thyroid Association. The main goal 
of the Endocrine Pathology Study Group and the KSC is to 
update the cytologic diagnostic guideline.8 According to recent 
data, 196,000 cases of thyroid FNAC are performed each year 
in Korea, accounting for 60% of all FNACs performed.9 Due to 
a perceived over-diagnosis of thyroid cancer, the performance of 
FNAC as a whole decreased by 19.6% in 2015 compared to 
2014, based on the data of our survey.
THYROID CYTOLOGY SAMPLE COLLECTORS 
AND INTERPRETERS
In the early stages of FNAC, endocrinologists, surgeons, radiol-
ogists, and pathologists aspirated palpable thyroid nodules and 
interpreted them using a Giemsa stain. After ultrasonography 
was introduced, radiologists began to aspirate thyroid nodules 
more than any other specialists. Now, national insurance covers 
the aspiration fee only when radiologists aspirate the thyroid 
nodule by guided ultrasonography. While radiologists perform 
the aspiration, legal standards dictate that a diagnosis can only 
be made by a cytopathologist. Therefore, cytologic interpretation 
has been carried out at more than 200 cytology laboratories 
throughout the country, all of which are subject to quality control 
by the KSC.
CYTOTECHNICIAN TRAINING PROGRAM
In 1981, the Korean National Medical Center, under the aus-
pices of the World Health Organization (WHO), launched a 
nationwide education program for cytotechnicians to work as 
cytology screeners. This is considered to be the first systematic 
cytologic education program in Korea. Under the direction of 
the WHO, this course was planned to increase early detection of 
cervical cancer, the most frequent cancer at the time, and it was 
a first step toward a national cancer eradication project (National 
Cancer Control Program) planned by the Health and Social 
Affairs Department (present Health and Welfare Department) 
in 1978. The need for systematic cytologic screening and edu-
cation was widely supported by the government. To establish 
the Cytology School of the National Medical Center’s Pathology 
Department, a Swedish cytotechnician, Barbro Nilsson, came 
to Korea in 1981 as a WHO adviser who worked as the primary 
cancer screening personnel (cytotechnician) educator. The WHO 
supported this adviser by providing educational equipment 
such as microscopes and lanterns; other healthcare professionals, 
like Swedish doctors Nils, who was the then president of the 
International Academy of Cytology (IAC), and Stormby, also 
donated slide teaching materials and textbooks for gynecological 
cytology. At that time, cytotechnician education was carried 
out at the National Medical Center with the main purpose of im-
proving the quality of cytopathology examination conducted at 
university hospitals and general hospital nationwide. Under the 
direction of anatomic pathologists, we selected 10 cytotechnicians 
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who were in charge of cytology screening, nine of whom attended 
their first training course in November 1981, and in the second 
course of the following year, we again selected other 10 cytotech-
nicians and educated.6
Thyroid FNAC is included in the cytotechnician education 
program; however, participation in cytology screening depends 
on the institutional policy. 
PREPARATION OF THYROID 
CYTOLOGY SAMPLES
At the time of introduction, FNACs were analyzed with air-dried 
Giemsa stain; since 2000, they have been read using an alcohol-
fixed conventional smear with Papanicolaou staining and cell 
block preparation. Currently, a few institutions still use the air-
dried Giemsa stain.
Liquid-based cytology (LBC), which decreases the rate of cell 
paucity, was introduced for FNAC preparation despite some 
inherent disadvantages such as unfamiliar cellular morphology. 
Since 2010, LBC had been widely adopted and was used by 44% 
of institutions in 2012 and by 68% in 2016. In the 2012 survey, 
LBC alone was not sufficient for diagnosis, so 22 of 33 institu-
tions (67%) used LBC combined with conventional methods. In 
2016, the number of institutions adding a supplemental method 
dropped to 12 of 23 (52%). This reduction can be attributed to 
increased experience in LBC interpretation.1 For FNAC spec-
imens, ThinPrep (45.0%) was most commonly used, followed by 
SurePath (33.6%), EASY Prep (12.9%), and Huro Path (4.5%).9
STAINING OF THYROID CYTOLOGY SAMPLES
Staining was initially performed using air-dried Giemsa stain, 
but the Papanicolaou stain has become predominant. However, 
some institutions still use hematoxylin and eosin or Giemsa 
stains.
THYROID CYTOLOGICAL REPORTING 
SYSTEMS AND DATA DISTRIBUTION
Until the Bethesda System for Reporting Thyroid Cytopa-
thology (TBSRTC) appeared in 2008,10 thyroid FNAC was diag-
nosed in a variety of ways; at some institutions, it was diagnosed 
using descriptive terms, in the same format as a pathology diagnosis.
The diagnosis of thyroid FNAC was made based mainly on 
the Papanicolaou Society Guidelines;11 as a result, the Korean 
Endocrine Society published management guidelines for patients 
with thyroid nodules and thyroid cancer in 2006.7
After that, the Endocrine Pathology Study Group was created 
in 2007. In 2008, eight thyroid-related societies made up the 
Korean Thyroid Association, and TBSRTC was introduced to 
Korea in 2009. The Endocrine Pathology Study Group and the 
KSC have been updating the cytologic diagnostic guideline 
Table 1. Cytologic diagnosis rates according to TBSRTC
Institution
Category
I II III IV V VI
1 8.6 61.7 6.1 5.5 3.4 14.7
2 16.2 51.9 18.9 0.6 3.3 9.1
3 8.0 61.0 2.3 0.6 4.5 23.6
4 15.4 51.5 16.5 0.5 4.8 11.4
5 8.1 60.0 11.8 1.1 2.9 16.2
6 11.2 56.9 7.6 1.0 4.3 19.0
7 20.1 34.1 21.9 0.7 5.7 17.4
8 20.3 44.5 18.1 2.0 3.0 12.2
9 32.6 61.5 3.2 0.2 1.9 0.6
10 2.9 86.5 2.7 0.0 0.6 7.3
11 0.0 74.9 9.7 0.0 3.4 12.0
12 5.5 50.0 6.6 22.3 6.8 8.9
Average (%) 12.4 57.9 10.4 2.9 3.7 12.7 
Range (%) 0–32.6 34.1–86.5 2.3–21.9 0–22.3 0.6–6.8 0.6–23.6
Average (%)12 12.9 59.3 9.6 10.1 2.7 5.4
Range (%)12 1.8–23.6 39.0–73.8 3.0–27.2 1.2–25.3 1.4–6.3 2.0–16.2
p-valuea .790 .723 .992 .053  .385 .008
TBSRTC, the Bethesda System for Reporting Thyroid Cytopathology.
aStatistical analysis of student’s t test for categorical diagnosis rate between this survey data and reference data were constructed from Excel Software. Differ-
ences for which p < .05 were considered significant.
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based on TBSRTC.8 According to the survey conducted in 2012, 
60 of the 74 responding institutions (80%) used TBSRTC,1 while 
the 2016 survey showed that 94% (34/36) are using TBSRTC.
Twelve institutions reported distribution data according to 
class in the Bethesda reporting system. Eight institutions also 
sent correlation data between cytology and histology. 
The categorical diagnosis rate of each institution by TBSRTC 
is as follows: I (12.4%), II (57.9%), III (10.4%), IV (2.9%), V 
(3.7%), and VI (12.7%), as shown in Table 1 and Fig. 1.
The average value is not very unique compare to worldwide 
reports,12 but some categories show significant differences between 
this present survey data and Bongiovanni’s meta-analysis data.12 
Categories 1, 2, 3, and 5 showed rates similar to Bongiovanni’s 
data. However, category 6 was significantly higher in this Korean 
survey than in Bongiovanni’s data (12.7% vs 5.4%, p = .008). 
Additionally, category 4 was lower in this Korean data than in 
Bongiovanni’s data, but the difference was not statistically signif-
icant (2.9% vs 10.1%, p = .053). 
This survey is limited in that the proportion of referral hospitals 
is higher than the distribution of nationwide laboratories in 
Korea.
USE OF ATYPIA OF UNDETERMINED 
SIGNIFICANCE AND FOLLICULAR LESION OF 
UNDETERMINED SIGNIFICANCE
In this survey, we looked at how to appropriately use the 
AUS/FLUS terminology of TBSRTC. In 66% of institutions, 
the two terms are used to indicate the same lesion, although 
most use only the term AUS. Only two institutions use the 
term AUS/FLUS.
In the remaining 34% of institutions, the two terms are used 
differently. AUS is used in cases with nuclear atypia, and FLUS 
is used in cases where there is architectural atypia. This is not 
consistent with the original intent of TBSRTC. In the case of 
AUS/FLUS, subcategorized studies are often reported by multiple 
institutions.13 Confusion exists surrounding this term, and it is 
necessary to establish consensus on the proper use of this term.
THYROID CYTOLOGY AUDIT PROGRAM: 
CORRELATION BETWEEN 
CYTOLOGY AND HISTOLOGY
The quality control system is managed by each institution, 
and reports on the quality control of thyroid FNACs have been 
published since 1996.14,15
Accuracy was assessed based on malignancy rates using cyto-
histological correlations, but some reports assessed the accuracy 
of each specific diagnostic entity. There are about 12 papers ad-
dressing this accuracy, of which about four demonstrated accu-
racy using TBSRTC.1,16-18
The malignancy rates for overall cytologic diagnoses are as 
follows for each category: I (1.8%), II (0.7%), III (6.3%), IV 
(19.1%), V (51.9%), and VI (63.5%) (Fig. 2A). The malignancy 
rates for surgical cases are as follows for each category: I (28.7%), 
II (27.8%), III (50.6%), IV (52.3%), V (90.7%), and VI (100.0%) 
(Fig. 2B).
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Fig. 1. The diagnosis rate of each institution by the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) category.
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EXTERNAL QUALITY ASSURANCE FOR 
THYROID FINE-NEEDLE 
ASPIRATION CYTOLOGY 
Since 1995, the KSC has been in charge of quality control of 
fine needle aspiration smears, and the quality control findings 
have been reported since 1999.6 Quality evaluation by the Korean 
Society of Pathologists was added in 2007, and each institute is 
making efforts to improve the quality of thyroid FNAC, as well 
as overall cytopathology.19
THE STATUS OF ANCILLARY TESTING 
INCLUDING CORE BIOPSY
Immunocytochemical staining could theoretically be used to 
make cytologic diagnoses, but immunocytochemical targets 
useful for thyroid cytology have not been identified. There have 
been many reports of galectin-3 being applied to cytologic diag-
nosis since 2008, but the results have been controversial.20-22
β-Catenin, CXCL12, and other rare immunocytochemical 
stains are also used for cytology. There are current reports of immu-
nocytochemistry for BRAF, and some institutions use it for actual 
analysis.23-26 Immunostaining for cytologic examination is also 
covered by insurance.
Since 2010, a molecular pathology approach, including the 
BRAFV600E mutation, has been utilized, and various molecular 
pathological studies are underway. However, only the BRAF test 
is actively used at present and approved by insurance.27-30
In recent years, core biopsies have been performed mainly in 
Korea and Italy. However, core biopsies were performed in only 
17 of the 36 institutions (44%) in this survey. Even institutions 
that perform core biopsy used the procedure in less than 3% of 
FNACs.
However, at two of these institutions, core biopsy was per-
formed up to three times more than FNAC. There are 45 articles 
on core biopsies written by Korean authors, most of which are 
reported by radiologists who prefer core biopsy.
These radiologists asked pathologists to establish a standard-
ized classification for core biopsy compatible with the TBSRTC. 
Pathologists agreeing with this idea have published a paper 
that standardizes core biopsy readings.31
In Korea, pathologists are interpreting both pathology and 
cytopathology. Therefore, for pathologists, histologic interpre-
tation of a core biopsy per se is easier than the cytological inter-
pretation of FNAC if difficulties or side effects accompanying 
the core biopsy procedure are not considered.
However, considering that we often cannot distinguish adeno-
matous hyperplasia from follicular neoplasm, even if we examine 
all surgical specimens, it is controversial to say that it is more 
accurate to make this distinction with core biopsy than with 
FNAC.
CONCLUSION
Currently, radiologists aspirate thyroid nodules under the 
guidance of ultrasonography, and legal standards dictate that a 
diagnosis can only be made by a cytopathologist.
The TBSRTC was used by up to 94% of institutions in 2016.
The average diagnosis rates are as follows for each category: I 
(12.4%), II (57.9%), III (10.4%), IV (2.9%), V (3.7%), and VI 
(12.7%). The malignancy rates in surgical cases are as follows for 
Fig. 2. (A) The malignancy rates for overall cytologic diagnoses are 
as follows for each category: I (1.8%), II (0.7%), III (6.3%), IV 
(19.1%), V (51.9%), and VI (63.5%). (B) The malignancy rates for 
surgical cases are as follows for each category: I (28.7%), II 
(27.8%), III (50.6%), IV (52.3%), V (90.7%), and VI (100.0%).
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each category: I (28.7%), II (27.8%), III (50.6%), IV (52.3%), V 
(90.7%), and VI (100.0%).
Since 2010, LBC has been used and was implemented by 68% 
of institutions in 2016.
It is necessary to draw consensus on the use of the terms AUS 
and FLUS.
Immunocytochemistry is used in galectin-3 and BRAF assays. 
For molecular tests in thyroid FNACs, BRAF is actively used. 
Core biopsies are performed only rarely in a few institutions.
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